DK2227234T3 - Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf - Google Patents

Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf

Info

Publication number
DK2227234T3
DK2227234T3 DK08840556.8T DK08840556T DK2227234T3 DK 2227234 T3 DK2227234 T3 DK 2227234T3 DK 08840556 T DK08840556 T DK 08840556T DK 2227234 T3 DK2227234 T3 DK 2227234T3
Authority
DK
Denmark
Prior art keywords
inputation
procedure
application
hepatocyte proliferation
hepatocyte
Prior art date
Application number
DK08840556.8T
Other languages
English (en)
Inventor
Pnina Fishman
Shira Cohen
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DK2227234T3 publication Critical patent/DK2227234T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08840556.8T 2007-10-15 2008-10-22 Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf DK2227234T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96079707P 2007-10-15 2007-10-15
PCT/IL2008/001361 WO2009050707A1 (en) 2007-10-15 2008-10-22 Method for inducing hepatocyte proliferation and uses thereof

Publications (1)

Publication Number Publication Date
DK2227234T3 true DK2227234T3 (da) 2014-08-11

Family

ID=40227958

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08840556.8T DK2227234T3 (da) 2007-10-15 2008-10-22 Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf

Country Status (9)

Country Link
US (2) US8846635B2 (da)
EP (1) EP2227234B1 (da)
JP (1) JP5592262B2 (da)
CN (1) CN101820883B (da)
DK (1) DK2227234T3 (da)
ES (1) ES2490606T3 (da)
IL (1) IL204063A (da)
PL (1) PL2227234T3 (da)
WO (1) WO2009050707A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
JP6000950B2 (ja) * 2010-08-12 2016-10-05 アーベーアーゲー フェアヴァルトゥングス ゲーエムベーハーＡｂａｇ Ｖｅｒｗａｌｔｕｎｇｓ Ｇｍｂｈ 肝細胞の特徴を有する細胞を産生するための方法並びに同方法により産生された細胞及びその使用
CN107459544B (zh) 2011-12-22 2021-03-16 詹森生物制药有限公司 取代的核苷、核苷酸及其类似物
EP2806878A1 (en) * 2012-01-23 2014-12-03 Can-Fite Biopharma Ltd. Treatment of liver conditions
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014028079A1 (en) * 2012-08-16 2014-02-20 Thomas Jefferson University Treatment of prostate cancer
IL242723B (en) * 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
US9789131B1 (en) 2016-04-21 2017-10-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
IL276358B1 (en) 2018-02-09 2024-07-01 Astrocyte Pharmaceuticals Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS
MX2021003515A (es) 2018-09-26 2021-05-27 Astrocyte Pharmaceuticals Inc Compuestos polimorficos y usos de los mismos.
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EP0708781B1 (en) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
DE60203702T2 (de) * 2001-01-16 2006-03-02 Can-Fite Biopharma Ltd. Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US7141553B2 (en) 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
US20050101560A1 (en) 2003-11-12 2005-05-12 Can-Fite Biopharma Ltd. Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
WO2006031505A1 (en) 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 and a1 adenosine receptor agonists
EP1819349A2 (en) * 2004-11-22 2007-08-22 King Pharmaceuticals Research and Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
EP1798233A1 (en) 2005-12-19 2007-06-20 Faust Pharmaceuticals Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof

Also Published As

Publication number Publication date
ES2490606T3 (es) 2014-09-04
US20140364388A1 (en) 2014-12-11
CN101820883A (zh) 2010-09-01
IL204063A (en) 2013-05-30
US20100249053A1 (en) 2010-09-30
JP2012506366A (ja) 2012-03-15
PL2227234T3 (pl) 2014-11-28
JP5592262B2 (ja) 2014-09-17
WO2009050707A1 (en) 2009-04-23
CN101820883B (zh) 2013-03-20
EP2227234B1 (en) 2014-05-07
US9387220B2 (en) 2016-07-12
EP2227234A1 (en) 2010-09-15
US8846635B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
DK2227234T3 (da) Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2158726T3 (da) Fremgangsmåde og system til bestemmelse af fysisk placering af udstyr
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
DK3211126T3 (da) Fremgangsmåder til dannelse og screening af dna-kodede biblioteker
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK3252057T3 (da) Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2297312T3 (da) Alpha-amylasevarianter af Bacillus subtilis og fremgangsmåder til anvendelse heraf
DK2247582T3 (da) Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2229800T3 (da) Fremgangsmåde og apparat til frigørelse af ressourcer
DK2622430T3 (da) Apparat og fremgangsmåder til udvidelse af applikationstjenester
DK2414507T3 (da) Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK2136801T3 (da) Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2195608T3 (da) System og fremgangsmåde til flerbilledoverflademåling af genstandes form
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation